title: Growth hormone treatment in pituitary insufficiency: selected cases of children with craniopharyngioma and medulloblastoma.
abstract: OBJECTIVE
  The work concerns the substitution treatment with growth hormone (GH) in hypopituitary children, including cases that occurred in the course of tumor disease, craniopharyngioma (CP) and medulloblastoma (MB).
  
  
  METHODS
  The studied population concerned 117 children who presented either somatotropic or polyhormonal pituitary insufficiency (the average age was 12.6 years for girls and 13.6 years for boys). The diagnosis of somatotropic pituitary insufficiency (SPI) was based on insulin and clonidin stimulation tests evaluating GH reserve of hypophysis. The computer tomography (CT) and nuclear magnetic resonance (NMR) examinations were carried out before GH substitution in all children. The tumors (four CP cases and one case of MB) were all found in boys and they were treated with surgery and/or radiotherapy. All studied children, including CP and MB operated patients were treated with human GH (hGH)--Genotropin 16 IU, administered in subcutaneous injections. The daily dose was calculated as 0.5 IU/kg/week.
  
  
  RESULTS
  The annual increase of children height before GH therapy was about 3.2 cm. In the first year of GH therapy the difference in children growth between the CP/MB group as compared with the rest of patients was less than 1.0 cm: 9.4 and 10.2 cm/year, resp. During the second year of hormone substitution the growth became slower: average values were 8.2 cm and 7.4 cm/year, resp. In CP and MB patients the height increase calculated as SDS values was significant (2.7 and 1.0 resp.). Control NMR examination performed in CP/MB patients treated with surgery with subsequent hGH therapy did not demonstrate any recurrence of tumor.
  
  
  CONCLUSIONS
  After two years of hGH therapy the final height of hypopituitary children, including CP patients, nearly reached the values observed in healthy children. GH therapy did not induce a recurrence of neoplasm in CP and MB patients.
authors.affiliation: Dept. Developmental Endocrinology and Diabetology, Institute of Pediatry, Medical University, Poznań, Poland.
authors.forename: A
authors.initials: A
authors.lastname: Kedzia
authors.forename: M
authors.initials: M
authors.lastname: Obara-Moszyńska
authors.forename: E
authors.initials: E
authors.lastname: Korman
authors.forename: B
authors.initials: B
authors.lastname: Rabska-Pietrzak
authors.forename: P
authors.initials: P
authors.lastname: Kopinski
authors.forename: J
authors.initials: J
authors.lastname: Trojan
authors.forename: A
authors.initials: A
authors.lastname: Goździcka-Józefiak
mesh_terms: D000293:Adolescent; D001932:Brain Neoplasms / Q000150:complications* / Q000628:therapy; D002648:Child; D002675:Child, Preschool; D003131:Combined Modality Therapy; D003397:Craniopharyngioma / Q000150:complications* / Q000628:therapy; D005260:Female; D019382:Human Growth Hormone / Q000627:therapeutic use*; D006801:Humans; D007018:Hypopituitarism / Q000188:drug therapy* / Q000209:etiology; D008297:Male; D008527:Medulloblastoma / Q000150:complications* / Q000628:therapy; D016896:Treatment Outcome
chemical_list: D019382:Human Growth Hormone